Related Experiment Video
Updated: Mar 22, 2026
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
Novel piperazine core compound induces death in human liver cancer cells: possible pharmacological properties
Nima Samie1, Sekaran Muniandy2, M S Kanthimathi2,3
1Department of Pharmacology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia.
Abstract:
The current study evaluates the cytotoxic mechanism of a novel piperazine derivate designated as PCC against human liver cancer cells. In this context, human liver cancer cell lines, SNU-475 and 243, human monocyte/macrophage cell line, CRL-9855, and human B lymphocyte cell line, CCL-156, were used to determine the IC50 of PCC using the standard MTT assay. PCC displayed a strong suppressive effect on SNU-475 and SNU-423 cells with an IC50 value of 6.98 ± 0.11 μg/ml and 7.76 ± 0.45 μg/ml respectively, after 24 h of treatment. Significant dipping in the mitochondrial membrane potential and elevation in the released of cytochrome c from the mitochondria indicated the induction of the intrinsic apoptosis pathway by PCC. Activation of this pathway was further evidenced by significant activation of caspase 3/7 and 9. PCC was also shown to activate the extrinsic pathways of apoptosis via activation of caspase-8 which is linked to the suppression of NF-ƙB translocation to the nucleus. Cell cycle arrest in the G1 phase was confirmed by flow cytometry and up-regulation of glutathione reductase expression was quantified by qPCR. This study suggests that PCC is a simultaneous inducer of intrinsic and extrinsic pathways of apoptosis in liver cancer cell lines.
Insights
A novel piperazine derivative, PCC, effectively suppresses liver cancer cells by inducing both intrinsic and extrinsic apoptosis pathways. This compound shows significant potential as a liver cancer therapeutic agent.
Area of Science:
- Pharmacology
- Molecular Biology
- Oncology
Background:
- Hepatocellular carcinoma (HCC) remains a significant global health challenge with limited effective therapeutic options.
- Understanding novel cytotoxic mechanisms is crucial for developing targeted cancer therapies.
Purpose of the Study:
- To elucidate the cytotoxic mechanism of a novel piperazine derivative, designated PCC, against human liver cancer cells.
- To evaluate the potential of PCC as a therapeutic agent for liver cancer.
Main Methods:
- Cytotoxicity was assessed using the MTT assay on human liver cancer cell lines (SNU-475, SNU-423).
- Apoptosis induction was confirmed by measuring mitochondrial membrane potential, cytochrome c release, and caspase activation (caspase 3/7, 9, and 8).
- Cell cycle arrest was analyzed via flow cytometry, and glutathione reductase expression was quantified using qPCR.
Main Results:
- PCC exhibited potent cytotoxicity against SNU-475 and SNU-423 cells with low IC50 values.
- PCC induced apoptosis through both intrinsic (mitochondrial) and extrinsic (death receptor) pathways.
- PCC caused G1 phase cell cycle arrest and upregulated glutathione reductase expression.
Conclusions:
- PCC is a novel compound that simultaneously activates intrinsic and extrinsic apoptosis pathways in liver cancer cells.
- PCC demonstrates significant anti-cancer activity, suggesting its potential as a lead compound for liver cancer treatment.
More Related Videos
12:40Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
Published on: May 19, 2018
09:32Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
Related Concept Videos
01:25Mutagenicity and Carcinogenicity
02:57Targeted Cancer Therapies
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:30Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...